Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
This article and the accompanying video present our protocol for generating tissue-engineered intestine in the mouse, using an organoid units-on-scaffold approach.
Tissue-engineered small intestine (TESI) has successfully been used to rescue Lewis rats after massive small bowel resection, resulting in return to preoperative weights within 40 days.1 In humans, massive small bowel resection can result in short bowel syndrome, a functional malabsorptive state that confers significant morbidity, mortality, and healthcare costs including parenteral nutrition dependence, liver failure and cirrhosis, and the need for multivisceral organ transplantation.2 In this paper, we describe and document our protocol for creating tissue-engineered intestine in a mouse model with a multicellular organoid units-on-scaffold approach. Organoid units are multicellular aggregates derived from the intestine that contain both mucosal and mesenchymal elements,3 the relationship between which preserves the intestinal stem cell niche.4 In ongoing and future research, the transition of our technique into the mouse will allow for investigation of the processes involved during TESI formation by utilizing the transgenic tools available in this species.5The availability of immunocompromised mouse strains will also permit us to apply the technique to human intestinal tissue and optimize the formation of human TESI as a mouse xenograft before its transition into humans. Our method employs good manufacturing practice (GMP) reagents and materials that have already been approved for use in human patients, and therefore offers a significant advantage over approaches that rely upon decellularized animal tissues. The ultimate goal of this method is its translation to humans as a regenerative medicine therapeutic strategy for short bowel syndrome.
1. Organoid Units Preparation
2. Loading of Polyglycolic Acid Scaffold
3. Implantation into Host Mouse
4. Harvest
Access restricted. Please log in or start a trial to view this content.
Figure 1 shows an overall schema for the protocol documented here. The end result of this protocol is a globe or spherical structure of tissue-engineered murine intestine with a lumen, mucosa, submucosa, and surrounding muscularis. Figure 2A shows a typical globe in comparison to a starting polymer scaffold. Figure 2B displays the same construct sharply bivalved to reveal its lumen. Figure 3 demonstrates a hematoxylin/eosin-stained paraffin-mounted cross...
Access restricted. Please log in or start a trial to view this content.
We present a protocol for producing tissue-engineered intestine in the mouse using an organoid units-on-scaffold approach. The most critical steps are those of the organoid units preparation. Care must be taken to adequately clean and mechanically process the tissue, but equal care must be taken not to overdigest or overtriturate the organoid units after the digestion is performed (step 1.11). If this is done, the organoid units can be reduced to single cells, which can be lost in the supernatant of step 1.12, and are un...
Access restricted. Please log in or start a trial to view this content.
No conflicts of interest declared.
Tracy C. Grikscheit, Erik R. Barthel, and Frédéric G. Sala are supported by the California Institute for Regenerative Medicine (CIRM), grant numbers RN2-00946-1 (TCG) and TG2-01168 (ERB, FGS). Allison L. Speer is a Society of University Surgeons Ethicon scholar. Yashuhiro Torashima is funded by a Children's Hospital Los Angeles Saban Institute Research Career Development Fellowship.
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
HBSS | Gibco | 114170-112 | |
Antibiotic-Antimycotic 100X | Invitrogen | 15240-062 | |
Dispase | Gibco | 17105-041 | |
Collagenase Type 1 | Worthington | LS004194 | |
DMEM High Glucose 1X | Gibco | 11995-065 | |
Heat inactivated FBS | Invitrogen | 16140-071 | |
Biofelt 100% PGA | Concordia Medical | FELT01-1005 | For polymer preparation as in Ref. 4 |
Poly-L-lactic acid | Durect | B6002-1 | For polymer preparation as in Ref. 4 |
Type I Collagen, rat tail | Sigma-Aldrich | C3867-1VL | For polymer preparation as in Ref. 4 |
Ketoprofen 100 mg/ml | Fort Dodge Animal Health | 71-KETOI-100-50 | |
LabDiet 5001 rodent chow | LabDiet | 5001 | |
Septra 200 mg / 40 mg per 5 ml, USP | Hi-Tech Pharmacal | 50383-824-16 | |
Isoflurane, USP | Phoenix Pharmaceuticals | 57319-507-06 |
Access restricted. Please log in or start a trial to view this content.
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone